SEZI Stock Overview
A medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Senzime AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 8.05 |
| 52 Week High | SEK 8.88 |
| 52 Week Low | SEK 4.02 |
| Beta | 0.63 |
| 11 Month Change | 7.33% |
| 3 Month Change | 9.67% |
| 1 Year Change | 60.68% |
| 33 Year Change | -66.74% |
| 5 Year Change | -14.36% |
| Change since IPO | -6.40% |
Recent News & Updates
Recent updates
Will Senzime (STO:SEZI) Spend Its Cash Wisely?
Feb 20
We Think Senzime (STO:SEZI) Can Afford To Drive Business Growth
Sep 01Companies Like Senzime (STO:SEZI) Are In A Position To Invest In Growth
May 18How Much Of Senzime AB (publ) (STO:SEZI) Do Insiders Own?
Mar 15Shareholders of Senzime (STO:SEZI) Must Be Delighted With Their 607% Total Return
Feb 16
We're Hopeful That Senzime (STO:SEZI) Will Use Its Cash Wisely
Jan 19Are Insiders Buying Senzime AB (publ) (STO:SEZI) Stock?
Dec 23What Kind Of Investors Own Most Of Senzime AB (publ) (STO:SEZI)?
Nov 26Shareholder Returns
| SEZI | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | -0.1% | -1.7% | -0.6% |
| 1Y | 60.7% | 1.3% | 17.0% |
Return vs Industry: SEZI exceeded the Swedish Medical Equipment industry which returned 1.3% over the past year.
Return vs Market: SEZI exceeded the Swedish Market which returned 17% over the past year.
Price Volatility
| SEZI volatility | |
|---|---|
| SEZI Average Weekly Movement | 6.1% |
| Medical Equipment Industry Average Movement | 7.1% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in SE Market | 12.1% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: SEZI's share price has been volatile over the past 3 months.
Volatility Over Time: SEZI's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 52 | Philip Siberg | www.senzime.com |
Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. It offers TetraGraph, a quantitative neuromuscular transmission monitor, which supports neuromuscular blockade management from induction to recovery; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance to measure the tissue’s opposition to carrying an alternating electrical current. The company has a strategic connectivity and licensing agreement with Masimo to develop, manufacture, market, and distribute products that can connect to the Masimo Root patient monitoring system and related digital hub for data transmission to hospital electronic patient journals; license agreement with Fukuda Denshi Co. Ltd.
Senzime AB (publ) Fundamentals Summary
| SEZI fundamental statistics | |
|---|---|
| Market cap | SEK 963.63m |
| Earnings (TTM) | -SEK 131.27m |
| Revenue (TTM) | SEK 40.59m |
23.7x
P/S Ratio-7.3x
P/E RatioIs SEZI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SEZI income statement (TTM) | |
|---|---|
| Revenue | SEK 40.59m |
| Cost of Revenue | SEK 29.73m |
| Gross Profit | SEK 10.86m |
| Other Expenses | SEK 142.13m |
| Earnings | -SEK 131.27m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 26, 2024
| Earnings per share (EPS) | -1.10 |
| Gross Margin | 26.75% |
| Net Profit Margin | -323.45% |
| Debt/Equity Ratio | 0% |
How did SEZI perform over the long term?
See historical performance and comparison